Medical/Pharmaceuticals
CARsgen Appoints Dr. Hua Jiang as Executive Director
SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Direct...
2022-08-02 20:50
2155
Ablaze Pharma Aligned The Strategic Agreement With Wenjiang District Government of Chengdu to Build-up the Innovative R&D and Manufacturing Center for Targeted Radiopharmaceutical Therapies
SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- In July 2022, Ablaze Pharma and Wenjiang District Government ofChengdu jointly signed the strategic agreement during the Conference of Major Advanced Manufacturing Projects by Foreign Direct Investment. About 26,000㎡ of industrial land is selected in the Che...
2022-08-02 20:39
1550
Chime Biologics Received Commercial Manufacturing License Indicating the Kick-off into the Era of Commercial Production
* GMP commercial manufacturing license authorized by the National Drug Regulatory Authority, demonstrating Chime Biologics' capabilities in large scale commercial production * Only 18 months to help LEPU Biopharma to obtain the approval of Puyouheng ™ ina new drug application demonstrating "...
2022-08-02 20:15
1504
NEXTSTELLIS® oral contraceptive has been nominated for the 2022 prix galien usa award for best pharmaceutical agent
ADELAIDE, Australia, Aug. 2, 2022 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXTSTELLIS® (drospirenone and estetrol tablets) has been nominated for the 2022 Prix GalienUSA Award for Best Pharmaceutical A...
2022-08-02 13:00
1569
"OpenDEL®3.0 - DRUG DISCOVERY PARTNER" webinar offered by HitGen and Endpoints News coming up on Thursday 4th August
CHENGDU, China, Aug. 1, 2022 /PRNewswire/ -- "OpenDEL®3.0 – DRUG DISCOVERY PARTNER" webinar will be jointly held by HitGen Inc. and Endpoints News on Thursday 4th August, to present you with a high-quality DEL product with all DEL information sharing and technical support. Dr. Guansai Liu, Execut...
2022-08-01 22:00
1957
OriCell Therapeutics Raises Over $120 Million in Series B Financing Led by Qiming Venture Partners and Quan Capital to Advance Cell Therapies for Cancer Immunology
2022 is set to be a milestone year for OriCell who has been focusing on the
field of cancer immunotherapy for more than seven years and is fully committed
to becoming an innovative global drug developer.
SHANGHAI, Aug. 1, 2022 /PRNewswire/ -- OriCell Therapeutics
2022-08-01 22:00
2335
New Immunotherapy Combination Study for Nasopharyngeal Cancer Demonstrates Effectiveness of Lunit AI as Predictive Aid in Treatment Outcome--Published in Clinical Cancer Research
* Recent clinical trial on combination immunotherapy for nasopharyngeal cancer provides evidence for Lunit SCOPE IO's ability to predict patient response. * Analysis indicates Immune-excluded Immune Phenotype acts as a resistance mechanism against combination immunotherapy, further supporting...
2022-08-01 21:00
1862
GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine
* GreenLight's messenger RNA production process is transferable to large-scale equipment and CMO facilities * Technology transfer and scale-up from lab bench to Samsung's commercial facility was completed in seven months * GreenLight's mRNA synthesis reaction had a titer of 12g/L at a commer...
2022-08-01 21:00
2266
Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer
Dr. Li brings deep oncology clinical development, medical affairs and U.S. regulatory experience SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 1, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical compa...
2022-08-01 20:00
1927
Meihua International Medical Technologies Co., Ltd. Reports 2021 Financial Year Results
YANGZHOU, China, Aug. 1, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries inChina, today reported its financial res...
2022-08-01 19:00
2544
Eccogene Announces US IND Approval for THRβ agonist ECC4703
SHANGHAI, Aug. 1, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I trial of its thyroid hormone receptor agonist ECC4703 in U.S. This study will evaluate the safety, tolerabilit...
2022-08-01 15:00
1546
Nippon Express (China) Opens New Healthcare Branch in Shanghai
- Company Is Stepping up Its Efforts in China's Pharmaceutical Industry - TOKYO, Aug. 1, 2022 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereafter "NX China"), a group company of NIPPON EXPRESS HOLDINGS, INC., has established a Healthcare Branch inShanghai to strengthen its efforts in Chin...
2022-08-01 14:22
1617
Nippon Express (China) Opens New Healthcare Branch in Shanghai
- Company Is Stepping up Its Efforts in China's Pharmaceutical Industry - TOKYO, Aug. 1, 2022 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereafter "NX China"), a group company of NIPPON EXPRESS HOLDINGS, INC., has established a Healthcare Branch inShanghai to strengthen its efforts in Chin...
2022-08-01 14:17
1578
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update
* Financial performance for Q2 2022 records revenues of KRW 26.2 billion, a 12% growth from the same period last year, driven by strong sales performance from the pharmaceutical division * Operating income turned to profit compared to the last quarter, while investment to R&D continued in t...
2022-07-29 20:00
2955
HistoIndex Stain-free AI-DP Reveals Treatment-induced Zonal Regression of Fibrosis Colocalized with Reduction in Steatosis & Hepatocyte Ballooning in FLIGHT-FXR NASH Clinical Trial
SINGAPORE, July 29, 2022 /PRNewswire/ -- HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, announced that its AI-based qFibrosis®, qSteatosis® and qBallooning® algorithms delivered sensitivity and granularity on a greater scale, as compared with the current ...
2022-07-29 19:00
2074
ZAODX World Conference on Early Detection of Cancer was successfully held in Guangzhou, China
GUANGZHOU, China, July 29, 2022 /PRNewswire/ -- The inaugural ZAODX World Conference on Early Detection of Cancer ("the Conference") was successfully held at the Chimelong International Conference Center inGuangzhou from July 15-17, 2022. In attendance were founders and representatives from over ...
2022-07-29 15:35
1516
MAYNE PHARMA AND GOODRX ANNOUNCE NEW INITIATIVE TO INCREASE AWARENESS OF NEXTSTELLIS® AND EXPAND ACCESS TO BIRTH CONTROL
* Mayne Pharma enters into strategic agreement with GoodRx * GoodRx and Mayne Pharma to collaborate and deliver an enhanced NEXTSTELLIS® direct-to-consumer (DTC) program ADELAIDE, Australia, July 29, 2022 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce a new strat...
2022-07-29 13:00
1604
QT MEDICAL'S Online Order, Mail Delivery, XPRESS ECG Testing Service, to Exhibit at the World's Largest Annual Trade Show
Enabling patients to conduct electrocardiogram (ECG) tests safely and efficiently at home using PCA 500, the only medical grade 12-lead Resting ECG approved by the FDA for patient use. LAS VEGAS, July 29, 2022 /PRNewswire/ -- Demand for telehealth and home care has surged drastically during the ...
2022-07-29 12:22
1758
Taiwan Startup PrecisemAb Continues Progress Towards Vision of Safest Antibody Treatment With No Side Effects
The Universal Antibody Lock technology will give patients more of a choice
TAIPEI, July 29, 2022 /PRNewswire/ -- PrecisemAb Biotech
2022-07-29 12:09
1491
Daewoong Pharmaceutical Co., Ltd. revs up the growth engine for Nabota, achieving the highest quarterly performance ever
- Daewoong Pharmaceutical Co., Ltd. achieved 293.8 billion won in sales and 33.6 billion won in operating revenue in the second quarter due to the growth of ethical drugs and Nabota. - A continuous increase in profitability is expected due to sales visualization of the new drug Fexuclue and Na...
2022-07-28 21:00
2530
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9236
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7714